India is the world’s largest producer of generic medicines by volume, supplying over 20% of the global generic drug market. For buyers \u2014 whether hospitals, clinics, pharmacies, or individual patients \u2014 understanding how these medicines are approved and regulated is the first step toward making safe, informed purchases.<\/p>\n\n\n\n
The Central Drugs Standard Control Organization (CDSCO) is India’s national regulatory body for pharmaceuticals and medical devices, operating under the Directorate General of Health Services, Ministry of Health and Family Welfare. As reported by Express Pharma on July 31, 2026, India’s Health Minister J P Nadda has committed to building a “future-ready drug regulatory framework to accelerate healthcare innovation” \u2014 a signal that CDSCO’s role in drug approval and quality oversight is only growing in importance.<\/p>\n\n\n\n
CDSCO is responsible for:<\/p>\n\n\n\n
For anyone buying Indian generic medicines \u2014 whether for personal use or institutional procurement \u2014 CDSCO approval is the baseline signal that a drug has met India’s regulatory requirements for safety, efficacy, and quality.<\/p>\n\n\n\n
The CDSCO approval process for generic medicines follows a structured pathway designed to verify that a generic drug is bioequivalent to its reference (innovator) product and meets quality standards. Here is how the process typically unfolds:<\/p>\n\n\n\n
The manufacturer submits a Drug Master File to CDSCO, containing detailed information about the drug’s composition, manufacturing process, quality control procedures, stability data, and packaging. This is the foundational document that CDSCO reviewers use to assess the drug’s suitability for the Indian market.<\/p>\n\n\n\n
For most generic drugs, CDSCO requires proof of bioequivalence \u2014 a clinical study demonstrating that the generic version delivers the same amount of active ingredient into the bloodstream at the same rate as the reference drug. This is a critical safety and efficacy gate: without bioequivalence data, a generic cannot be approved. As covered by India Briefing in February 2026, the NDCT (New Drugs and Clinical Trials) Rules 2026 amendments have streamlined some clinical trial pathways, but bioequivalence requirements for generics remain a cornerstone of the approval framework.<\/p>\n\n\n\n
CDSCO’s subject expert committees review the submitted data \u2014 including DMF content, bioequivalence reports, toxicology data (if applicable), and labeling proposals. The review assesses whether the generic drug is therapeutically equivalent to the reference product and whether its manufacturing process is sound.<\/p>\n\n\n\n
Before or after approval, CDSCO or its designated inspectors may conduct site visits to the manufacturer’s facility to verify that Good Manufacturing Practices (GMP) are being followed. India’s Schedule M (the national GMP standard) aligns with WHO-GMP guidelines, and many Indian manufacturers also hold WHO prequalification or USFDA\/EMA approvals for their facilities.<\/p>\n\n\n\n
Once all reviews are complete and compliance is confirmed, CDSCO grants marketing authorization. The drug receives approval for specific strength(s), formulation(s), and indication(s). The approved drug is then listed in the national drug database and can be legally manufactured and sold in India.<\/p>\n\n\n\n
Several significant regulatory changes are shaping how generic drugs are approved and monitored in India this year:<\/p>\n\n\n\n
Beyond CDSCO approval itself, informed buyers should verify several additional markers of quality and reliability:<\/p>\n\n\n\n
When sourcing Indian generic medicines, be alert to these warning signs:<\/p>\n\n\n\n